# Current strategies for improving osseointegration of mesoporous silica drug delivery systems: A scoping review protocol

**Authors:** Adrianna Skwira-Rucińska, Jakub Ruszkowski, Adrian Szewczyk, Magdalena Prokopowicz

PMC · DOI: 10.1371/journal.pone.0338462 · 2026-02-04

## TL;DR

This paper outlines a scoping review protocol to evaluate strategies for improving the bone integration of mesoporous silica drug delivery systems.

## Contribution

The study introduces a structured approach to analyze recent strategies for enhancing the osseointegration of mesoporous silica in bone regeneration.

## Key findings

- The review will focus on studies from 2015 onwards to assess the osseointegration potential of mesoporous silica.
- It will examine strategies such as structural modifications and bioactive molecule incorporation to improve bone regeneration.
- The analysis will identify trends and gaps in current approaches for optimizing mesoporous silica systems.

## Abstract

Mesoporous silica (MS) is widely recognized as a local drug delivery system in bone-related diseases. Although MS enables controlled or sustained release and improved bioavailability of therapeutic agents, its limited native osseointegration capacity remains a critical barrier to effective bone regeneration. Numerous engineering strategies have therefore been proposed to enhance its biological performance. This scoping review protocol aims to collect studies, published from January 2015 onwards, that report evidence on the osseointegration potential (i.e., osteoconductive, osteoinductive, or proangiogenic properties) of MS bone drug delivery systems. Studies indexed in PubMed, Scopus, and Embase will be screened to identify the strategies used to improve MS-mediated bone regeneration, including structural modifications, formulation into composites, and incorporation of bioactive molecules. A structured analytical framework will be applied to explore how specific design approaches relate to biological outcomes across experimental models in vitro, in vivo, or ex vivo. The resulting scoping review will identify trends and knowledge gaps in strategies intended to enhance the osseointegration of MS bone drug delivery systems, supporting their future development and rational optimization for bone repair.

## Full-text entities

- **Diseases:** periodontal disease (MESH:D010510), bone defect (MESH:D001847), osteoporosis (MESH:D010024), bone tumor (MESH:D001859)
- **Chemicals:** bisphosphonates (MESH:D004164), oxygen (MESH:D010100), Si (MESH:D012825), SBA-15 (MESH:C509969), silanol (MESH:C082343), silica (MESH:D012822), MS (-), MCM-41 (MESH:C509968), nitrogen (MESH:D009584)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HMEC-1 — Homo sapiens (Human), Transformed cell line (CVCL_0307), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), MG-63 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0426), HOB — Homo sapiens (Human), Adult immunoblastic lymphoma, Cancer cell line (CVCL_J391), U2OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0042), hFOB 1.19 — Homo sapiens (Human), Conditionally immortalized cell line (CVCL_3708), SaOS-2 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0548), MC3T3-E1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0409)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12871979/full.md

---
Source: https://tomesphere.com/paper/PMC12871979